Dr. Andrew Wolfe

Contact Information

Andrew Wolfe, Ph.D.
Assistant Professor, Department of Biological Sciences, Hunter College of the City University of New York
Adjunct Assistant Professor, Department of Pharmacology, Weill Cornell Medicine
Faculty in the CUNY Graduate Center Biochemistry Ph.D. Program
Faculty in the CUNY Graduate Center Molecular, Cellular, and Developmental Biology Ph.D. Subprogram

Wolfe Lab website: bit.ly/thewolfelab
Email: awolfe@genectr.hunter.cuny.edu
Phone: (212) 896-0456
Mailing Address:
413 E 69 Street
Belfer Research Building, Room BB-414
New York NY 10021

Education

• University of California, Los Angeles, Biology/Psychology, B.S., 2003-2007.
• Weill Cornell Graduate School of Medical Sciences, Ph.D. in the Cancer Biology and Genetics Department at Memorial Sloan Kettering Cancer Center, 2007-2014.
• Mount Sinai School of Medicine, Department of Oncological Sciences, Postdoctoral Fellow, 2014-2016.
• University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, Postdoctoral Fellow, 2016-2021.

Research Interests

Why do so many cancers recur after seemingly successful treatment? How can understanding the biology of oncogenes lead to new therapeutic possibilities?

The Wolfe lab strives to gain a deeper understanding of how tumors depend on driver oncogenes to reprogram their growth, metabolism, and survival signals. Understanding mechanisms by which pancreatic cancers, lung cancers, and leukemias develop resistance to targeted therapies is instrumental to developing innovative approaches that can improve patient outcomes.

The lab employs techniques related to molecular biology, pharmacology, biochemistry, cancer signaling, tissue culture, large-scale screening, models of cancer, flow cytometry, CRISPR, and more.

For more information, please visit the Wolfe Lab website at bit.ly/thewolfelab

Publications

• Cadherin-17 as a target for the immunoPET of adenocarcinoma
  European Journal of Nuclear Medicine and Molecular Imaging. April 16, 2024.
  Delaney S, Keinänen O, Lam D, Wolfe AL, Hamakubo T, Zeglis BM
• KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
  Current Oncology. April 3, 2024.
  Ash LJ, Busia-Bourdain O, Okpattah D, Kamel A, Liberchuk A, Wolfe AL
• Targeting cancer’s sweet spot: UGP2 as a therapeutic vulnerability
  Molecular and Cellular Oncology. October 27, 2021.
  Kim S, Wolfe AL*, Kim SE*
• UDP-glucose pyrophosphorylase 2, a regulator of glycogen synthesis and glycosylation, iscritical for pancreatic cancer growth
  Proceedings of the National Academy of Sciences of the United States of America. August 3, 2021.
  Wolfe AL, Zhou Q, Toska E, Galeas J, Ku AA, Koche RP, Bandyopadhyay S, Scaltriti M, Lebrilla CB, McCormick F*, Kim SE*
• NOTCH and EZH2 collaborate to repress PTEN expression in breast cancer
  Communications Biology. March 9, 2021.
  Pappas K, Martin TC, Wolfe AL, Nguyen CB, Su T, Jin J, Hibshoosh H, Parsons R
• NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy
  Cancers. February 5, 2021.
  Sanghvi VR, Mohan P, Singh K, Cao L, Berishaj M, Wolfe AL, Schatz JH, Lailler N, de Stanchina E, Viale A, Wendel HG
• Cystic Fibrosis Transmembrane Conductance Regulator Attaches Tumor Suppressor PTEN to the Membrane and Promotes Anti Pseudomonas aeruginosa Immunity
  Immunity. December 19, 2017.
  Riquelme SA, Hopkins BD, Wolfe AL, DiMango E, Kitur K, Parsons R, Prince A
• Characterization of a set of tumor suppressor microRNAs in T cell acute lymphoblastic leukemia
  Science Signaling. November 18, 2014.
  Sanghvi VR, Mavrakis KJ, Van der Meulen J, Boice M, Wolfe AL, Carty M, Mohan P, Rondou P, Socci ND, Benoit Y, Taghon T, Van Vlierberghe P, Leslie CS, Speleman F, Wendel HG
• RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer
  Nature. September 4, 2014.
  Wolfe AL*, Singh K*, Zhong Y, Drewe P, Rajasekhar VK, Sanghvi VR, Mavrakis KJ, Jiang M, Roderick JE, Van der Meulen J, Schatz JH, Rodrigo CM, Zhao C, Rondou P, de Stanchina E, Teruya-Feldstein J, Kelliher MA, Speleman F, Porco JA Jr, Pelletier J, Rätsch G, Wendel HG
• The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma
  Cell. October 28, 2011
  Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, Jiang M, Liu X, Bruno J, Heguy A, Olshen AB, Socci ND, Teruya-Feldstein J, Weis-Garcia F, Tam W, Shaknovich R, Melnick A, Himanen JP, Chaganti RS, Wendel HG
• Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma
  Journal of Experimental Medicine. August 29, 2011.
  Schatz JH, Oricchio E, Wolfe AL, Jiang M, Linkov I, Maragulia J, Shi W, Zhang Z, Rajasekhar VK, Pagano NC, Porco JA Jr, Teruya-Feldsteim, J, Rosen N, Zelenetz AD, Pelletier J, Wendel HG
• A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL)
  Nature Genetics. June 5, 2011.
  Mavrakis KJ, Van Der Meulen J, Wolfe AL, Liu X, Mets E, Taghon T, Khan AA, Setty M, Rondou P, Vandenberghe P, Delabesse E, Benoit Y, Socci NB, Leslie CS, Van Vlierberghe P, Speleman F, Wendel HG
• Mouse models of cancer as biological filters for complex genomic data
  Disease Models and Mechanisms. Nov-Dec 2010.
  Oricchio E, Wolfe AL, Schatz JH, Mavrakis KJ, Wendel HG
• Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia
  Nature Cell Biology. February 28, 2010.
  Mavrakis KJ*, Wolfe AL*, Oricchio E, Palomero T, de Keersmaecker K, McJunkin K, Zuber J, James T, Khan AA, Leslie CS, Parker JS, Paddison PJ, Tam W, Ferrando A, Wendel HG

*Indicates co-first authorship.